Sorry, you need to enable JavaScript to visit this website.

CISATRACURIUM BESYLATE (cisatracurium besylate) Nonclinical Toxicology


13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility


Long-term animal studies to evaluate the carcinogenic potential of cisatracurium besylate have not been performed.


Cisatracurium besylate was evaluated in a battery of four genotoxicity assays. Evaluation of cisatracurium besylate in the in vitro mouse lymphoma forward gene mutation assay resulted in mutations in the presence and absence of exogenous metabolic activation. The in vitro bacterial reverse gene mutation (Ames) assay, in vitro human lymphocyte chromosomal aberration assay, and an in vivo rat bone marrow cytogenetic assay did not demonstrate evidence of mutagenicity or clastogenicity.

Impairment of Fertility

Studies to determine if cisatracurium besylate impacts fertility have not been completed.

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event